AbbVie Says Risankizumab More Effective Than Placebo For Crohn's Disease Management

By: via Benzinga
AbbVie Inc (NYSE: ABBV) disclosed that it presented a proof of concept, Phase II trial in Crohn's disease with investigatory biologic ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.